Prevalence of Babesia Babesia in Canadian blood donors: June–October 2018

摘要

BACKGROUND The erythrocytic protozoan parasite Babesia microti , the cause of human babesiosis, is transmitted not only by tick bites but also via blood transfusion. B. microti is endemic in the northeastern/upper midwestern United States, where partial screening of blood donations has been implemented. In Canada, a 2013 study of approximately 14,000 donors found no B. microti antibody‐positive samples, suggesting low risk at that time. METHODS Between June and October 2018, 50,752 Canadian donations collected from sites near the US border were tested for Babesia nucleic acid by transcription‐mediated amplification (TMA). Reactive donations were tested for B . microti by IgG immunofluorescence assay and polymerase chain reaction. A subset of 14,758 TMA nonreactive samples was also screened for B. microti antibody. Donors who tested reactive/positive were deferred, asked about risk factors, and were requested to provide a follow‐up sample for supplemental testing. RESULTS One sample from Winnipeg, Manitoba, was TMA and antibody reactive. Of the 14,758 TMA‐nonreactive donations tested for antibody, four reactive donations were identified from southwestern Ontario near Lake Erie. None of the interviewed donors remembered any symptoms, likely tick exposure, or relevant travel within Canada or the United States. CONCLUSIONS This is the largest B. microti prevalence study performed in Canada. The results indicate very low prevalence, with only one TMA‐confirmed‐positive donation of 50,752 tested. This donor was from the only region in Canada where autochthonous infection has been reported. Seropositive donations in southwestern Ontario suggest low prevalence; travel should not be ruled out given the proximity to the US border.